GE HealthCare Technologies Inc.(GEHC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #995 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
GEHC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for GE HealthCare Technologies Inc. (GEHC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GEHC at 58.2/100 on a 32-signal composite quality model, placing it at rank #995 of 2,879 stocks — the top half of the AI-ranked universe. GEHC scores in the top quartile across revenue scale (92.9). Areas of concern include institutional flow (6.6) and free cash flow (33.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), GE HealthCare Technologies Inc. reports quarterly revenue of $5.1B, net income of $389.0M, an operating margin of 10.0%. Top institutional holders of GEHC by reported 13-F value include BlackRock,, DODGE & COX, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GEHC trades on the Nasdaq exchange and files with the SEC under CIK 1932393. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GEHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GE HealthCare Technologies Inc. directly from SEC EDGAR. GE HealthCare Technologies Inc.'s 13F Pro composite quality score has ranged between 8 and 64 since 2024, currently 58.2 — a stable long-term trajectory across 44 quarterly and live scoring snapshots.
Revenue
Q1 2026
$5.1B
Net Income
Q1 2026
$389.0M
Free Cash Flow
Q1 2026
$112.0M
Operating Margin
Q1 2026
10.0%
D/E Ratio
Q1 2026
0.95
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+4.8% YoYNet Income
+4.6% YoYOperating Income
+5.3% YoYEPS (Diluted)
+4.8% YoYTotal Assets
+11.5% YoYTotal Debt
-7.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $20.63B +4.8% | $19.67B +0.6% | $19.55B +6.6% | $18.34B +4.3% | $17.59B | — |
| Net Income | $2.08B +4.6% | $1.99B +27.1% | $1.57B -18.2% | $1.92B -14.7% | $2.25B | — |
| Operating Income | $2.76B +5.3% | $2.63B +7.8% | $2.44B -3.4% | $2.52B -9.8% | $2.79B | — |
| EPS (Diluted) | $4.55 +4.8% | $4.34 +43.2% | $3.03 | $0.00 | $0.00 | — |
| Total Assets | $36.91B +11.5% | $33.09B +2.0% | $32.45B +17.8% | $27.54B | — | — |
| Total Debt | $11.01B -7.9% | $11.95B +4.4% | $11.45B +38.4% | $8.27B | — | — |
AI Insight: GEHC Financial Trends
Revenue grows 7% year-over-year to $5,131M in Q1 2026, but operating income collapses to a multi-quarter low of $515M, signaling meaningful margin pressure.
• Revenue rose from $4,777M in Q1 2025 to $5,131M in Q1 2026, a 7.4% year-over-year gain.
• Operating income fell sharply to $515M in Q1 2026 from $629M in Q1 2025, the lowest level in the observable period.
• Net income dropped to $389M in Q1 2026 versus $564M in Q1 2025 — a 31% year-over-year decline.
• Total debt declined meaningfully from $14,289M in Q3 2025 to $10,143M in Q1 2026, reducing leverage.
⚠ Operating margin in Q1 2026 is approximately 10%, down from ~13% in Q1 2025 — a sharp one-year contraction to monitor.
⚠ Operating cash flow of $290M in Q1 2026 is positive but modest relative to net income; Q3 2024 and Q4 2025 OCF remain unreported.
⚠ Equity steadily expanded from $7,801M in Q2 2024 to $10,668M in Q1 2026, a constructive balance-sheet trend worth sustaining.
AI Insight: GEHC Ratio Trends
ROIC has compressed 580bps from its Q4 2024 peak of 15.7% to just 9.9% in Q1 2026, signaling meaningful returns deterioration.
• Operating margin fell sharply to 10.0% in Q1 2026, its lowest in the dataset, down from 15.1% in Q4 2024.
• ROIC declined from 15.7% in Q4 2024 to 9.9% in Q1 2026, a contraction of 580bps over five quarters.
• D/E ratio improved meaningfully from 1.48 in Q3 2024 to 0.95 in Q1 2026, indicating notable deleveraging.
• Net profit margin dropped to 7.6% in Q1 2026, the weakest quarterly reading in the table.
⚠ Q1 seasonality is historically weak, but Q1 2026 OpMargin of 10.0% is well below Q1 2025's 13.2% — a concerning year-over-year step-down.
⚠ ROE collapsed to 14.6% in Q1 2026 from 34.2% in Q4 2024; confirm whether lower leverage or earnings weakness is the primary driver.
⚠ D/E falling to 0.95 is a positive structural shift; monitor whether debt reduction continues or reverses in coming quarters.
Get alerted when GEHC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for GE HealthCare Technologies Inc. including:
Top Institutional Holders of GEHC
BlackRock, Inc.
$2.6B35,984,327 shDODGE & COX
$2.2B31,312,064 shVANGUARD CAPITAL MANAGEMENT LLC
$2.1B28,864,188 shCapital Research Global Investors
$1.5B21,108,753 shSTATE STREET CORP
$1.5B20,538,476 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.4B19,183,157 shHARRIS ASSOCIATES L P
$1.1B15,594,988 shGEODE CAPITAL MANAGEMENT, LLC
$879.3M12,399,635 shBARROW HANLEY MEWHINNEY & STRAUSS LLC
$845.9M11,884,588 shHOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
$709.5M9,967,873 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $2.6B | 35,984,327 |
| DODGE & COX | $2.2B | 31,312,064 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.1B | 28,864,188 |
| Capital Research Global Investors | $1.5B | 21,108,753 |
| STATE STREET CORP | $1.5B | 20,538,476 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.4B | 19,183,157 |
| HARRIS ASSOCIATES L P | $1.1B | 15,594,988 |
| GEODE CAPITAL MANAGEMENT, LLC | $879.3M | 12,399,635 |
| BARROW HANLEY MEWHINNEY & STRAUSS LLC | $845.9M | 11,884,588 |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $709.5M | 9,967,873 |
More Healthcare Companies
View all Healthcare →Put GEHC on your watchlist
Track score changes the day GE HealthCare Technologies Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GEHC a good stock to buy?
13F Pro's AI-powered analysis of GE HealthCare Technologies Inc. (GEHC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GEHC are available on the GEHC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GEHC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GEHC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GE HealthCare Technologies Inc.'s investment landscape.